Phase 2 Hearing Loss Trial, Recruiting (NCT06517888)

Phase 2 Hearing Loss Trial, Recruiting NCT06517888 Sponsor: Akouos, Inc. Condition: Hearing Loss

Printed from Voxsanity (voxsanity.com.au) — NCT06517888 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hearing Loss

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have a non-cancerous inner ear tumour (called a vestibular schwannoma) on one side only, and it has been growing over time.
Your tumour is larger than 2 mm in size.
You have severe hearing loss in the ear affected by the tumour, confirmed by a hearing test.
You are able and willing to follow all the requirements of the trial, including taking part in a separate long-term follow-up study after the main trial ends.

Who may not be able to join:

You have been diagnosed with a condition called NF2 (Neurofibromatosis Type 2) or have tumours of this kind on both sides of your head.
You have previously had surgery or radiation treatment for your inner ear tumour.
You have a history of a condition that causes your hearing in the affected ear to fluctuate or causes repeated episodes of dizziness (confirm with trial site).
You have severe hearing loss in your unaffected ear (the ear without the tumour), confirmed by a hearing test.
You have taken part in a clinical trial involving an experimental drug within the last six months, or you have ever previously taken part in a gene therapy trial.

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Aaron Tward, MD, Eli Lilly and Company

Phone: +1 (857) 410-1816

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06517888

Sponsor: Akouos, Inc.

Phase: Phase 2

Status: Recruiting

Condition: Hearing Loss

Trial contact: +1 (857) 410-1816

More information: https://clinicaltrials.gov/study/NCT06517888

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have a non-cancerous inner ear tumour (called a vestibular schwannoma) on one side only, and it has been growing over time.
Your tumour is larger than 2 mm in size.
You have severe hearing loss in the ear affected by the tumour, confirmed by a hearing test.
You are able and willing to follow all the requirements of the trial, including taking part in a separate long-term follow-up study after the main trial ends.

Who may not be able to join:

You have been diagnosed with a condition called NF2 (Neurofibromatosis Type 2) or have tumours of this kind on both sides of your head.
You have previously had surgery or radiation treatment for your inner ear tumour.
You have a history of a condition that causes your hearing in the affected ear to fluctuate or causes repeated episodes of dizziness (confirm with trial site).
You have severe hearing loss in your unaffected ear (the ear without the tumour), confirmed by a hearing test.
You have taken part in a clinical trial involving an experimental drug within the last six months, or you have ever previously taken part in a gene therapy trial.

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Akouos, Inc.

Registry

ClinicalTrials.gov

Start date

17 January 2025

Est. completion

1 August 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Frequency of Adverse Events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov